Gout: An old disease in new perspective – A review

Journal of Advanced Research

Volumn 8, Issue 5, 2017, Pages 495-511

  Ragab, Gaafar ^a   Elshahaly, Mohsen ^b   Bardin, Thomas ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b Suez Canal University Faculty of Medicine   (Egypt)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Clinical picture of gout; Gout; Hyperuricemia; Imaging modalities; Management of gout; Pathogenesis

Indexed keywords

EID: 85020419916     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2017.04.008     Document Type: Review

References (180)

1. Dalbeth, N., Merriman, T.R., Stamp, L.K., Gout Lancet 388:10055 (2016), 2039–2052.
2. Emmerson, B.T., The management of gout. New Engl J Med 334:7 (1996), 445–451.
3. Pascual, E., Sivera, F., Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 66:8 (2007), 1056–1058.
4. Singh, J.A., Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol: Practical Rep Rheum Musculoskelet Dis 20:3 (2014), 172–174.
5. Kuo, C.F., Grainge, M.J., Zhang, W., Doherty, M., Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11:11 (2015), 649–662.
6. McCarty, D.J., Hollander, J.L., Identification of urate crystals in gouty synovial fluid. Ann Intern Med 54 (1961), 452–460.
7. Mandal, A.K., Mount, D.B., The molecular physiology of uric acid homeostasis. Annu Rev Physiol 77 (2015), 323–345.
8. Kamei, K., Konta, T., Hirayama, A., Suzuki, K., Ichikawa, K., Fujimoto, S., et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol, Dialysis, Transplant: official publication of the European Dialysis and Transplant Association – European Renal Association 29:12 (2014), 2286–2292.
9. Torres, R.J., Puig, J.G., Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis, 2, 2007, 48.
10. Reginato, A.M., Olsen, B.R., Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear?. Curr Opin Rheumatol 19:2 (2007), 134–145.
11. Kanbara, A., Seyama, I., Effect of urine pH on uric acid excretion by manipulating food materials. Nucleosides, Nucleotides Nucleic Acids 30:12 (2011), 1066–1071.
12. Towiwat, P., Li, Z.G., The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. Int J Rheum Dis 18:5 (2015), 495–501.
13. Mahmoud, H.H., Leverger, G., Patte, C., Harvey, E., Lascombes, F., Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 77:Suppl 4 (1998), 18–20.
14. Emmerson, B., Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 57:9 (1998), 509–510.
15. Bedir, A., Topbas, M., Tanyeri, F., Alvur, M., Arik, N., Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J 44:4 (2003), 527–536.
16. Dessein, P.H., Shipton, E.A., Stanwix, A.E., Joffe, B.I., Ramokgadi, J., Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59:7 (2000), 539–543.
17. Ichida, K., Matsuo, H., Takada, T., Nakayama, A., Murakami, K., Shimizu, T., et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nature Commun, 3, 2012, 764.
18. Enomoto, A., Endou, H., Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 9:3 (2005), 195–205.
19. Bobulescu, I.A., Moe, O.W., Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 19:6 (2012), 358–371.
20. Han, J., Liu, Y., Rao, F., Nievergelt, C.M., O'Connor, D.T., Wang, X., et al. Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney Int 83:4 (2013), 733–740.
21. Cho, S.K., Kim, S., Chung, J.Y., Jee, S.H., Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1. BMJ Open, 5(11), 2015, e009360.
22. Tan, P.K., Ostertag, T.M., Miner, J.N., Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep, 6, 2016, 34995.
23. Phipps-Green, A.J., Merriman, M.E., Topless, R., Altaf, S., Montgomery, G.W., Franklin, C., et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis 75:1 (2016), 124–130.
24. Kolz, M., Johnson, T., Sanna, S., Teumer, A., Vitart, V., Perola, M., et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet, 5(6), 2009, e1000504.
25. Liu, R., O'Connell, M., Johnson, K., Pritzker, K., Mackman, N., Terkeltaub, R., Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 43:5 (2000), 1145–1155.
26. Cronstein, B.N., Sunkureddi, P., Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol: Practical Rep Rheumat Musculoskelet Dis 19:1 (2013), 19–29.
27. Busso, N., Ea, H.K., The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis). Reumatismo 63:4 (2012), 230–237.
28. Ea, H.K., Mechanisms of gout inflammation. Presse Med 40:9 Pt 1 (2011), 836–843.
29. Dalbeth, N., Lauterio, T.J., Wolfe, H.R., Mechanism of action of colchicine in the treatment of gout. Clin Ther 36:10 (2014), 1465–1479.
30. Steiger, S., Harper, J.L., Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep, 16(1), 2014, 392.
31. Grassi, W., De Angelis, R., Clinical features of gout. Reumatismo 63:4 (2012), 238–245.
32. Gonzalez, E.B., An update on the pathology and clinical management of gouty arthritis. Clin Rheumatol 31:1 (2012), 13–21.
33. Schlesinger, N., Thiele, R.G., The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:11 (2010), 1907–1912.
34. Kosmadakis, G., Viskaduraki, M., Michail, S., The validity of fractional excretion of uric acid in the diagnosis of acute kidney injury due to decreased kidney perfusion. Am J Kidney Dis 54:6 (2009), 1186–1187.
35. Burns, C.M., Wortmann, R.L., Latest evidence on gout management: what the clinician needs to know. Therap Adv Chronic Dis 3:6 (2012), 271–286.
36. Kanbay, M., Huddam, B., Azak, A., Solak, Y., Kadioglu, G.K., Kirbas, I., et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol: CJASN 6:8 (2011), 1887–1894.
37. Luk, A.J., Levin, G.P., Moore, E.E., Zhou, X.H., Kestenbaum, B.R., Choi, H.K., Allopurinol and mortality in hyperuricaemic patients. Rheumatol (Oxford, England) 48:7 (2009), 804–806.
38. Yokose, C., Chen, M., Berhanu, A., Pillinger, M.H., Krasnokutsky, S., Gout and osteoarthritis: associations, pathophysiology, and therapeutic implications. Curr Rheumatol Rep, 18(10), 2016, 65.
39. Mazzali, M., Kanbay, M., Segal, M.S., Shafiu, M., Jalal, D., Feig, D.I., et al. Uric acid and hypertension: cause or effect?. Curr Rheumatol Rep 12:2 (2010), 108–117.
40. Katsiki, N., Papanas, N., Fonseca, V.A., Maltezos, E., Mikhailidis, D.P., Uric acid and diabetes: Is there a link?. Curr Pharm Des 19:27 (2013), 4930–4937.
41. Roddy, E., Revisiting the pathogenesis of podagra: why does gout target the foot?. J Foot Ankle Res, 4(1), 2011, 13.
42. Canoso, J.J., Yood, R.A., Acute gouty bursitis: report of 15 cases. Ann Rheum Dis 38:4 (1979), 326–328.
43. Perez-Ruiz, F., Castillo, E., Chinchilla, S.P., Herrero-Beites, A.M., Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am 40:2 (2014), 193–206.
44. Pascual, E., Batlle-Gualda, E., Martinez, A., Rosas, J., Vela, P., Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 131:10 (1999), 756–759.
45. Chhana, A., Dalbeth, N., The gouty tophus: a review. Curr Rheumatol Rep, 17(3), 2015, 19.
46. Malik, A., Schumacher, H.R., Dinnella, J.E., Clayburne, G.M., Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol: Practical Rep Rheum Musculoskelet Dis 15:1 (2009), 22–24.
47. Zhang, W., Doherty, M., Pascual, E., Bardin, T., Barskova, V., Conaghan, P., et al. EULAR evidence based recommendations for gout. Part I: diagnosis. report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65:10 (2006), 1301–1311.
48. Atdjian, M., Fernandez-Madrid, F., Coexistence of chronic tophaceous gout and rheumatoid arthritis. J Rheumatol 8:6 (1981), 989–992.
49. Dincer, H.E., Dincer, A.P., Levinson, D.J., Asymptomatic hyperuricemia: to treat or not to treat. Clevel Clin J Med, 69(8), 2002, 594 7, 600-2 passim.
50. Badulescu, M., Macovei, L., Rezus, E., Acute gout attack with normal serum uric acid levels. Rev Med Chir Soc Med Nat Iasi 118:4 (2014), 942–945.
51. Underwood, M., Diagnosis and management of gout. BMJ (Clin Res Ed) 332:7553 (2006), 1315–1319.
52. Pascual, E., Tovar, J., Ruiz, M.T., The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluid. Ann Rheum Dis 48:12 (1989), 983–985.
53. Phelps, P., Steele, A.D., McCarty, D.J. Jr., Compensated polarized light microscopy. Identification of crystals in synovial fluids from gout and pseudogout. JAMA 203:7 (1968), 508–512.
54. Strasinger, S.K., Di Lorenzo, M.S., Urinalysis & body fluids. 2008, F. A. Davis Company.
55. Kramer, H.M., Curhan, G., The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 40:1 (2002), 37–42.
56. Fernandes EA, Bergamaschi SB, Rodrigues TC, Dias GC, Malmann R, Ramos GM, et al. Relevant aspects of imaging in the diagnosis and management of gout. Revista brasileira de reumatologia. 2016.
57. Rettenbacher, T., Ennemoser, S., Weirich, H., Ulmer, H., Hartig, F., Klotz, W., et al. Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol 18:3 (2008), 621–630.
58. Namas, R., Meysami, A., Siegal, D., Rubin, B., Gout and ultrasound: the disease of kings and the queen of imaging. Gout Hyperuricaemia 1 (2014), 94–100.
59. Bloch, C., Hermann, G., Yu, T.F., A radiologic reevaluation of gout: a study of 2,000 patients. AJR Am J Roentgenol 134:4 (1980), 781–787.
60. Malghem J, Vande Berg B, Lecouvet F. Goutte d'hier et d'aujourd'hui. Imagerie de l'appareil musculo-squlettique: Textes choisis. Montpellier (France): Sauramps Medical; 2011. p. 35–44.
61. Omoumi, P., Zufferey, P., Malghem, J., So, A., Imaging in gout and other crystal-related arthropathies. Rheum Dis Clin North Am 42:4 (2016), 621–644.
62. Martel, W., The overhanging margin of bone: a roentgenologic manifestation of gout. Radiology 91:4 (1968), 755–756.
63. Gentili, A., Advanced imaging of gout. Semin Musculoskelet Radiol 7:3 (2003), 165–174.
64. Choi, M.H., MacKenzie, J.D., Dalinka, M.K., Imaging features of crystal-induced arthropathy. Rheum Dis Clin North Am 32:2 (2006), 427–446 viii.
65. Gentili, A., The advanced imaging of gouty tophi. Curr Rheumatol Rep 8:3 (2006), 231–235.
66. Durcan, L., Grainger, R., Keen, H.I., Taylor, W.J., Dalbeth, N., Imaging as a potential outcome measure in gout studies: A systematic literature review. Semin Arthritis Rheum 45:5 (2016), 570–579.
67. Dalbeth, N., Clark, B., McQueen, F., Doyle, A., Taylor, W., Validation of a radiographic damage index in chronic gout. Arthritis Rheum 57:6 (2007), 1067–1073.
68. Nestorova, R., Fodor, D., Crystal-induced arthritis. El Miedany, Y., (eds.) Musculoskeletal ultrasonography in rheumatic diseases, 2015, Springer International Publishing, Cham, 137–167.
69. Grassi, W., Gutierrez, M., Filippucci, E., Chapter 16 - crystal-associated synovitis A2 – Wakefield, Richard J. D'Agostino, M.A., (eds.) Essential applications of musculoskeletal ultrasound in rheumatology, 2010, Content Repository Only!, Philadelphia, 187–197.
70. Filippucci, E., Di Geso, L., Grassi, W., Tips and tricks to recognize microcrystalline arthritis. Rheumatol (Oxford, England) 51:Suppl 7 (2012), vii18–vii21.
71. Gutierrez, M., Smith, W., Thiele, R., Keen, H., Kaeley, G., Naredo, E., et al. Defining elementary ultrasound lesions in gout. Preliminary results of Delphi consensus and web-exercise reliability. Ann Rheum Dis, 73(Suppl 2), 2014, 302.
72. Wright, S.A., Filippucci, E., McVeigh, C., Grey, A., McCarron, M., Grassi, W., et al. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis 66:7 (2007), 859–864.
73. Filippucci, E., Riveros, M.G., Georgescu, D., Salaffi, F., Grassi, W., Hyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound study. Osteoarthr Cartilage 17:2 (2009), 178–181.
74. Thiele, R.G., Schlesinger, N., Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 30:4 (2010), 495–503.
75. Thiele, R.G., Schlesinger, N., Diagnosis of gout by ultrasound. Rheumatol (Oxford, England) 46:7 (2007), 1116–1121.
76. Naredo, E., Uson, J., Jimenez-Palop, M., Martinez, A., Vicente, E., Brito, E., et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?. Ann Rheum Dis 73:8 (2014), 1522–1528.
77. Abate, M., Schiavone, C., Salini, V., Andia, I., Occurrence of tendon pathologies in metabolic disorders. Rheumatol (Oxford, England) 52:4 (2013), 599–608.
78. Dalbeth, N., Clark, B., Gregory, K., Gamble, G., Sheehan, T., Doyle, A., et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 68:8 (2009), 1290–1295.
79. McQueen, F.M., Doyle, A., Dalbeth, N., Imaging in gout–what can we learn from MRI, CT, DECT and US?. Arthritis Res Therapy, 13(6), 2011, 246.
80. Gerster, J.C., Landry, M., Dufresne, L., Meuwly, J.Y., Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 61:1 (2002), 52–54.
81. Dalbeth, N., Clark, B., Gregory, K., Gamble, G.D., Doyle, A., McQueen, F.M., Computed tomography measurement of tophus volume: Comparison with physical measurement. Arthritis Care Res 57:3 (2007), 461–465.
82. Perez-Ruiz, F., Calabozo, M., Pijoan, J.I., Herrero-Beites, A.M., Ruibal, A., Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Care Res 47:4 (2002), 356–360.
83. Gerster, J.C., Landry, M., Duvoisin, B., Rappoport, G., Computed tomography of the knee joint as an indicator of intraarticular tophi in gout. Arthritis Rheum 39:8 (1996), 1406–1409.
84. Omoumi, P., Becce, F., Ott, J.G., Racine, D., Verdun, F.R., Optimization of radiation dose and image quality in musculoskeletal CT: emphasis on iterative reconstruction techniques (Part 1). Semin Musculoskelet Radiol 19:5 (2015), 415–421.
85. Omoumi, P., Verdun, F.R., Becce, F., Optimization of radiation dose and image quality in musculoskeletal CT: emphasis on iterative reconstruction techniques (Part 2). Semin musculoskelet Radiol 19:5 (2015), 422–430.
86. Omoumi, P., Becce, F., Racine, D., Ott, J.G., Andreisek, G., Verdun, F.R., Dual-Energy CT: basic principles, technical approaches, and applications in musculoskeletal imaging (Part 1). Semin Musculoskelet Radiol 19:5 (2015), 431–437.
87. Nicolaou, S., Invited commentary. Radio Graph 31:5 (2011), 1376–1377.
88. Huppertz, A., Hermann, K.G., Diekhoff, T., Wagner, M., Hamm, B., Schmidt, W.A., Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int 34:6 (2014), 763–771.
89. Bongartz, T., Glazebrook, K.N., Kavros, S.J., Murthy, N.S., Merry, S.P., Franz, W.B. 3rd, et al. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis 74:6 (2015), 1072–1077.
90. Melzer, R., Pauli, C., Treumann, T., Krauss, B., Gout tophus detection-a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum 43:5 (2014), 662–665.
91. McQueen, F.M., Doyle, A.J., Reeves, Q., Gamble, G.D., Dalbeth, N., DECT urate deposits: now you see them, now you don't. Ann Rheum Dis 72:3 (2013), 458–459.
92. Glazebrook, K.N., Guimaraes, L.S., Murthy, N.S., Black, D.F., Bongartz, T., Manek, N.J., et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology 261:2 (2011), 516–524.
93. Chowalloor, P.V., Siew, T.K., Keen, H.I., Imaging in gout: A review of the recent developments. Therap Adv Musculoskelet Dis 6:4 (2014), 131–143.
94. Toprover, M., Krasnokutsky, S., Pillinger, M.H., Gout in the spine: imaging, diagnosis, and outcomes. Curr Rheumatol Rep, 17(12), 2015, 70.
95. Zheng, Z.F., Shi, H.L., Xing, Y., Li, D., Jia, J.Y., Lin, S., Thoracic cord compression due to ligamentum flavum gouty tophus: a case report and literature review. Spinal Cord 53:12 (2015), 881–886.
96. Nunes, E.A., Rosseti, A.G. Jr., Ribeiro, D.S., Santiago, M., Gout initially mimicking rheumatoid arthritis and later cervical spine involvement. Case Rep Rheumatol, 2014, 2014, 357826.
97. Ahmad, I., Tejada, J.G., Spinal gout: a great mimicker. A case report and literature review. Neuroradiol J 25:5 (2012), 621–625.
98. Nygaard, H.B., Shenoi, S., Shukla, S., Lower back pain caused by tophaceous gout of the spine. Neurology, 73(5), 2009, 404.
99. Hsu, C.Y., Shih, T.T., Huang, K.M., Chen, P.Q., Sheu, J.J., Li, Y.W., Tophaceous gout of the spine: MR imaging features. Clin Radiol 57:10 (2002), 919–925.
100. Gongidi, P., Gough-Fibkins, S., Spondyloarthritis: a gouty display. J Radiol Case Rep 4:5 (2010), 13–18.
101. Zhao, Z., Wang, Y., Jin, J., Deng, X., Huang, F., An analysis of abnormal magnetic resonance imaging of sacroiliac joints in patients misdiagnosed as spondyloarthritis. Zhonghua nei ke za zhi 53:9 (2014), 724–729.
102. Kang, H.J., Jung, S.H., Yoon, H.K., Hahn, S.B., Kim, S.J., Carpal tunnel syndrome caused by space occupying lesions. Yonsei Med J 50:2 (2009), 257–261.
103. Chen, C.K., Chung, C.B., Yeh, L., Pan, H.B., Yang, C.F., Lai, P.H., et al. Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients. AJR Am J Roentgenol 175:3 (2000), 655–659.
104. Godfrin-Valnet, M., Godfrin, G., Godard, J., Prati, C., Toussirot, E., Michel, F., et al. Eighteen cases of crowned dens syndrome: Presentation and diagnosis. Neurochirurgie 59:3 (2013), 115–120.
105. Udayakumar, D., Kteleh, T., Alfata, S., Bali, T., Joseph, A., Spinal gout mimicking paraspinal abscess: A case report. J Radiol Case Rep 4:6 (2010), 15–20.
106. Chen, C.H., Chen, C.K., Yeh, L.R., Pan, H.B., Yang, C.F., Intra-abdominal gout mimicking pelvic abscess. Skeletal Radiol 34:4 (2005), 229–233.
107. Grainger, R., Dalbeth, N., Keen, H., Durcan, L., Lawrence Edwards, N., Perez-Ruiz, F., et al. Imaging as an outcome measure in gout studies: report from the OMERACT gout working group. J Rheumatol 42:12 (2015), 2460–2464.
108. Dalbeth, N., Choi, H.K., Terkeltaub, R., Review: gout: a roadmap to approaches for improving global outcomes. Arthritis Rheumatol 69:1 (2017), 22–34.
109. Doherty, M., Jansen, T.L., Nuki, G., Pascual, E., Perez-Ruiz, F., Punzi, L., et al. Gout: why is this curable disease so seldom cured?. Ann Rheum Dis 71:11 (2012), 1765–1770.
110. Khanna, D., Fitzgerald, J.D., Khanna, P.P., Bae, S., Singh, M.K., Neogi, T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:10 (2012), 1431–1446.
111. Khanna, D., Khanna, P.P., Fitzgerald, J.D., Singh, M.K., Bae, S., Neogi, T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:10 (2012), 1447–1461.
112. Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castaneda-Sanabria, J., et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:1 (2017), 29–42.
113. De Vera, M.A., Marcotte, G., Rai, S., Galo, J.S., Bhole, V., Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken) 66:10 (2014), 1551–1559.
114. Terkeltaub, R.A., Furst, D.E., Bennett, K., Kook, K.A., Crockett, R.S., Davis, M.W., High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62:4 (2010), 1060–1068.
115. Terkeltaub, R.A., Furst, D.E., Digiacinto, J.L., Kook, K.A., Davis, M.W., Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 63:8 (2011), 2226–2237.
116. Boonmuang, P., Nathisuwan, S., Chaiyakunapruk, N., Suwankesawong, W., Pokhagul, P., Teerawattanapong, N., et al. Characterization of statin-associated myopathy case reports in Thailand using the health product vigilance center database. Drug Saf 36:9 (2013), 779–787.
117. Kuncl, R.W., Duncan, G., Watson, D., Alderson, K., Rogawski, M.A., Peper, M., Colchicine myopathy and neuropathy. N Engl J Med 316:25 (1987), 1562–1568.
118. Janssens, H.J., Janssen, M., van de Lisdonk, E.H., van Riel, P.L., van Weel, C., Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 371:9627 (2008), 1854–1860.
119. Man, C.Y., Cheung, I.T., Cameron, P.A., Rainer, T.H., Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 49:5 (2007), 670–677.
120. Rainer, T.H., Cheng, C.H., Janssens, H.J., Man, C.Y., Tam, L.S., Choi, Y.F., et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 164:7 (2016), 464–471.
121. Richette, P., Bardin, T., Should prednisolone be first-line therapy for acute gout?. Lancet, 372(9646), 2008, 1301 author reply -2.
122. Daoussis, D., Antonopoulos, I., Yiannopoulos, G., Andonopoulos, A.P., ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine 80:3 (2013), 291–294.
123. So, A., De Smedt, T., Revaz, S., Tschopp, J., A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther, 9(2), 2007, R28.
124. Ottaviani, S., Molto, A., Ea, H.K., Neveu, S., Gill, G., Brunier, L., et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther, 15(5), 2013, R123.
125. Schlesinger, N., Alten, R.E., Bardin, T., Schumacher, H.R., Bloch, M., Gimona, A., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:11 (2012), 1839–1848.
126. Qaseem, A., Harris, R.P., Forciea, M.A., Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians. Ann Intern Med 166:1 (2017), 58–68.
127. Rees, F., Jenkins, W., Doherty, M., Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 72:6 (2013), 826–830.
128. Dalbeth, N., Wong, S., Gamble, G.D., Horne, A., Mason, B., Pool, B., et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis 69:9 (2010), 1677–1682.
129. Zhu, Y., Zhang, Y., Choi, H.K., The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford) 49:12 (2010), 2391–2399.
130. Beyl, R.N. Jr., Hughes, L., Morgan, S., Update on importance of diet in gout. Am J Med 129:11 (2016), 1153–1158.
131. Azadbakht, L., Mirmiran, P., Esmaillzadeh, A., Azizi, T., Azizi, F., Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 28:12 (2005), 2823–2831.
132. Kontogianni, M.D., Chrysohoou, C., Panagiotakos, D.B., Tsetsekou, E., Zeimbekis, A., Pitsavos, C., et al. Adherence to the Mediterranean diet and serum uric acid: the ATTICA study. Scand J Rheumatol 41:6 (2012), 442–449.
133. Kiltz, U., Smolen, J., Bardin, T., Cohen Solal, A., Dalbeth, N., Doherty, M., et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis, 2016.
134. Latourte, A., Bardin, T., Richette, P., Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford) 53:11 (2014), 1920–1926.
135. Nidorf, S.M., Eikelboom, J.W., Budgeon, C.A., Thompson, P.L., Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61:4 (2013), 404–410.
136. Richette, P., Perez-Ruiz, F., Doherty, M., Jansen, T.L., Nuki, G., Pascual, E., et al. Improving cardiovascular and renal outcomes in gout: what should we target?. Nat Rev Rheumatol 10:11 (2014), 654–661.
137. Roberts, C.J., Marshall, A.J., Heaton, S., Barritt, D.W., Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone. BMJ 1:6158 (1979), 224–226.
138. Reach, G., Treatment adherence in patients with gout. Joint Bone Spine 78:5 (2011), 456–459.
139. Greene, M.L., Fujimoto, W.Y., Seegmiller, J.E., Urinary xanthine stones–a rare complications of allopurinol therapy. N Engl J Med 280:8 (1969), 426–427.
140. Wright, D.F., Duffull, S.B., Merriman, T.R., Dalbeth, N., Barclay, M.L., Stamp, L.K., Predicting allopurinol response in patients with gout. Br J Clin Pharmacol 81:2 (2016), 277–289.
141. Roberts, R.L., Wallace, M.C., Phipps-Green, A.J., Topless, R., Drake, J.M., Tan, P., et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J, 2016.
142. Annemans, L., Spaepen, E., Gaskin, M., Bonnemaire, M., Malier, V., Gilbert, T., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67:7 (2008), 960–966.
143. Delbarre, F., Amor, B., Auscher, C., de Gery, A., Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis 25:6 Suppl (1966), 627–633.
144. Becker, M.A., Schumacher, H.R. Jr, Wortmann, R.L., MacDonald, P.A., Eustace, D., Palo, W.A., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:23 (2005), 2450–2461.
145. Schumacher, H.R. Jr, Becker, M.A., Wortmann, R.L., Macdonald, P.A., Hunt, B., Streit, J., et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:11 (2008), 1540–1548.
146. Becker, M.A., Fitz-Patrick, D., Choi, H.K., Dalbeth, N., Storgard, C., Cravets, M., et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum 45:2 (2015), 174–183.
147. Reinders, M.K., van Roon, E.N., Jansen, T.L., Delsing, J., Griep, E.N., Hoekstra, M., et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68:1 (2009), 51–56.
148. Tam, S., Carroll, W., Allopurinol hepatotoxicity. Am J Med 86:3 (1989), 357–358.
149. Greenberg, M.S., Zambrano, S.S., Aplastic agranulocytosis after allopurinol therapy. Arthritis Rheum 15:4 (1972), 413–416.
150. Gelbart, D.R., Weinstein, A.B., Fajardo, L.F., Allopurinol-induced interstitial nephritis. Ann Intern Med 86:2 (1977), 196–198.
151. Azulay, J.P., Blin, O., Valentin, P., Abegg, P., Pellissier, J.F., Serratrice, G., Regression of allopurinol-induced peripheral neuropathy after drug withdrawal. Eur Neurol 33:3 (1993), 193–194.
152. Sidoroff, A., Halevy, S., Bavinck, J.N., Vaillant, L., Roujeau, J.C., Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol 28:3 (2001), 113–119.
153. Bastuji-Garin, S., Rzany, B., Stern, R.S., Shear, N.H., Naldi, L., Roujeau, J.C., Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:1 (1993), 92–96.
154. Kardaun, S.H., Sidoroff, A., Valeyrie-Allanore, L., Halevy, S., Davidovici, B.B., Mockenhaupt, M., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 156:3 (2007), 609–611.
155. Kim, S.C., Newcomb, C., Margolis, D., Roy, J., Hennessy, S., Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken) 65:4 (2013), 578–584.
156. Yang, C.Y., Chen, C.H., Deng, S.T., Huang, C.S., Lin, Y.J., Chen, Y.J., et al. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med 175:9 (2015), 1550–1557.
157. Hung, S.I., Chung, W.H., Liou, L.B., Chu, C.C., Lin, M., Huang, H.P., et al. HLA-B∗5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102:11 (2005), 4134–4139.
158. Ng, C.Y., Yeh, Y.T., Wang, C.W., Hung, S.I., Yang, C.H., Chang, Y.C., et al. Impact of the HLA-B(∗)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol 136:7 (2016), 1373–1381.
159. Stamp, L.K., Taylor, W.J., Jones, P.B., Dockerty, J.L., Drake, J., Frampton, C., et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 64:8 (2012), 2529–2536.
160. Hande, K.R., Noone, R.M., Stone, W.J., Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:1 (1984), 47–56.
161. Chung, W.H., Chang, W.C., Stocker, S.L., Juo, C.G., Graham, G.G., Lee, M.H., et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis 74:12 (2015), 2157–2164.
162. Ko, T.M., Tsai, C.Y., Chen, S.Y., Chen, K.S., Yu, K.H., Chu, C.S., et al. Use of HLA-B∗58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ, 351, 2015, h4848.
163. Dalbeth, N., Kumar, S., Stamp, L., Gow, P., Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 33:8 (2006), 1646–1650.
164. Stamp, L.K., O'Donnell, J.L., Zhang, M., James, J., Frampton, C., Barclay, M.L., et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63:2 (2011), 412–421.
165. Juge, P.A., Truchetet, M.E., Pillebout, E., Ottaviani, S., Vigneau, C., Loustau, C., et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine, 2016.
166. Chou, H.Y., Chen, C.B., Cheng, C.Y., Chen, Y.A., Ng, C.Y., Kuo, K.L., et al. Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). J Clin Pharm Ther 40:6 (2015), 689–692.
167. Bardin, T., Chales, G., Pascart, T., Flipo, R.M., Korng Ea, H., Roujeau, J.C., et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 83:3 (2016), 314–317.
168. MacDonald, T.M., Ford, I., Nuki, G., Mackenzie, I.S., De Caterina, R., Findlay, E., et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open, 4(7), 2014, e005354.
169. Gutman, A.B., Yu, T.F., Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis. Trans Assoc Am Physicians 64 (1951), 279–288.
170. Pui, K., Gow, P.J., Dalbeth, N., Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol 40:6 (2013), 872–876.
171. Perez-Ruiz, F., Alonso-Ruiz, A., Calabozo, M., Herrero-Beites, A., Garcia-Erauskin, G., Ruiz-Lucea, E., Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:9 (1998), 545–549.
172. Perez-Ruiz, F., Calabozo, M., Fernandez-Lopez, M.J., Herrero-Beites, A., Ruiz-Lucea, E., Garcia-Erauskin, G., et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 5:2 (1999), 49–55.
173. Bardin, T., Keenan, R.T., Khanna, P.P., Kopicko, J., Fung, M., Bhakta, N., et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis, 2016.
174. Saag, K.G., Fitz-Patrick, D., Kopicko, J., Fung, M., Bhakta, N., Adler, S., et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol 69:1 (2017), 203–212.
175. Takahashi, S., Moriwaki, Y., Yamamoto, T., Tsutsumi, Z., Ka, T., Fukuchi, M., Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 62:6 (2003), 572–575.
176. Milionis, H.J., Kakafika, A.I., Tsouli, S.G., Athyros, V.G., Bairaktari, E.T., Seferiadis, K.I., et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 148:4 (2004), 635–640.
177. Richette, P., Briere, C., Hoenen-Clavert, V., Loeuille, D., Bardin, T., Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 34:10 (2007), 2093–2098.
178. Sundy, J.S., Baraf, H.S., Yood, R.A., Edwards, N.L., Gutierrez-Urena, S.R., Treadwell, E.L., et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306:7 (2011), 711–720.
179. Vallon, V., Thomson, S.C., Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:2 (2017), 215–225.
180. Strauss, M.B., Familiar medical quotations. 1968, Little Brown & Co., USA.